5 Key Takeaways

• 1

  A case series reported occlusive retinal vasculitis following rechallenge with faricimab in patients with prior mild intraocular inflammation.

• 2

  Three patients experienced irreversible vision loss after receiving additional doses of faricimab, despite treatment with steroids.

• 3

  The study involved 3 patients treated between October 2023 and August 2024, with 4 eyes developing occlusive retinal vasculitis.

• 4

  Potential mechanisms for occlusive retinal vasculitis include antidrug antibodies, protein aggregates, or delayed hypersensitivity reactions.

• 5

  The researchers advised caution when rechallenging patients with faricimab after prior intraocular inflammation.